

INDEX

Note: Entries followed by “f” indicate figures; “t” tables.

- AAP (American Academy of Pediatrics) guidelines, 50t, 196-197, 197t
Abbot Labs (Signify) rapid tests, 41-43. *See also* RADTs (rapid antigen detection tests).
- Abdominal pain, 30t, 186
- Acceava (BioStar) rapid test, 41-43. *See also* RADTs (rapid antigen detection tests).
- Accuracy, diagnoses, 61-62, 62t. *See also* Diagnoses.
- Acute rheumatic fever. *See* ARF (acute rheumatic fever).
- ADD (attention deficit disorder), 206t-207t
- Adenopathy, 29-30, 31t, 205-208
- ADHD (attention deficit hyperactivity disorder), 204-207, 206t-207t
- Adherence factors, 63-65, 64t
adherence and compliance, 63-65, 64t
adherence inhibition, 216-217
- Age-inappropriate separation anxiety, 204-205, 206t-207t
- AHA (American Heart Association) guidelines, 50t, 82t-83t
- Allergic reactions, 65-75, 66t-68t, 73t-74t, 82t-83t, 91, 95-98, 96t-97t
cross allergic reactions, 65-75, 66t-68t, 73t-74t
penicillin allergies, 82t-83t, 91, 95-98, 96t-97t. *See also* Penicillin and amoxicillin.
- α -Hemolytic streptococci, 94, 180-181
- American Academy of Family Physicians guidelines, 50t
- American Academy of Pediatrics. *See* AAP (American Academy of Pediatrics) guidelines.
- American Heart Association. *See* AHA (American Heart Association) guidelines.
- Aminoglycosides, 22t
- Amoxicillin and penicillin, 81-90. *See also* Antibiotic therapies.
AHA guidelines for, 82t-83t
amoxicillin, 21-24, 22t, 85-91, 88t, 100t-102t
amoxicillin-clavulanate, 64t, 76t-77t, 89-91, 100t-102t, 183-186
vs ampicillin, 85-89, 88t
vs cephalosporins, 119-128, 120t-125t, 126f-127f, 130t, 132t-133t, 135f-136f. *See also* Cephalosporins.
chemical structure of, 73t
clinical trials and research studies of, 81-89, 82t-84t, 86t-88t
vs cloxacillin, 89
complications and, 201-202
cost-related factors of, 89
vs dicloxacillin, 89
failure rates of, 84t, 201-202
fundamentals of, 66t-68t, 81-84, 82t-84t
vs nafcillin, 89
penicillin, 21-24, 22t, 49, 76t-77t, 81-98, 82t-83t, 86t-87t, 96t-97t, 119-128, 184, 193-195, 194t
allergies, 82t-83t, 91, 95-98, 96t-97t
benzathine penicillin G, 82t-83t, 84-85, 86t-87t, 184
benzathine penicillin plus rifampin, 194-195, 194t
penicillin G, 49, 184

Amoxicillin and penicillin, penicillin (*continued*)

penicillin G, oral, 84-85, 86t-87t, 89
penicillin plus rifampin, 193-195, 194t
penicillin V, 82t-83t, 84-85, 86t-87t, 184-186
penicillin VK, 76t-77t
procaine penicillin, 84-85
recurrent infections and, 178-185. *See also* Recurrent infections.
reference resources for, 89-90
strengths and limitations of, 62t

Ampicillin, 73t, 85-89, 88t

Analyses, 128-135, 130t, 132t-133t, 135f-136f

sensitivity, 132t-133t
stratified, 128-135, 130t, 132t-133t, 135f-136f

Anspor, 120t. *See also* Cephradine.

Anti-DNase B (antideoxyribonuclease B), 202, 208

Antibiotic therapies, 49-176. *See also under individual drug names and classes.*

aminoglycosides, 22t

bacterial resistance and, 91-95, 92t

β -lactams, 22-24, 22t, 91-92, 202

carriage and, 193-195, 194t-195t. *See also* Carriage.

cephalosporins, 22-24, 22t, 91, 119-144, 122t-125t, 130t, 135f-136f,

160t-163t, 166t, 183-185, 195-196, 195t, 198, 204-205

analyses, sensitivity, 132t-133t

analyses, stratified, 128-135, 130t, 132t-133t, 135f-136f

cefaclor, 22-24, 22t, 100t-102t, 122t-125t, 128-137, 130t

cefadroxil, 22-24, 22t, 120t, 122t-125t, 128-137, 130t, 160t-161t

cefatrizine, 122t-124t

cefdinir, 22-24, 22t, 120t, 125t, 128-137, 130t, 135f-136f, 160t-161t

cefditoren, 120t

cefetamet/cefetamet pivoxil, 124t, 128-137, 130t

cefixime, 120t, 125t, 128-137, 130t, 160t-161t, 194-195, 194t

cefotiam, 160t-161t

cefpodoxime/cefpodoxime proxetil, 22-24, 22t, 120t, 122t-125t, 128-137,

130t, 160t-161t

cefpodoxime/cefpodoxime proxetil, 22-24, 22t, 120t, 122t-125t, 128-137, 130t, 193-195, 194t

cefprozil, 22-24, 22t, 120t, 124t-125t, 128-137, 130t, 193-195, 194t

ceftibuten, 22-24, 22t, 120t, 124t-125t, 128-137, 130t

ceftriaxone, 22-24, 22t

cefuroxime/cefuroxime axetil, 22-24, 22t, 120t, 124t-125t, 128-137, 130t,

160t-161t

cephalexin, 22-24, 22t, 120t, 122t-125t, 128-137, 130t

cephaloglycin, 122t-125t, 128-137

cephradine, 120t

vs ciprofloxacin, 22-24, 22t

clinical trials and research studies of, 119-137, 120t-125t, 126f-127f,

130t, 132t-133t, 135f-136f

duration criteria for, 160t-163t, 166t, 168f-171f

first-generation, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f

fundamentals of, 66t-68t, 119-128, 120t-125t, 126f-127f, 134-137

loracarbef, 120t, 124t-125t, 128-137, 130t

vs penicillin, 119-128, 120t-125t, 126f-127f, 130t, 132t-133t, 135f-136f

reference resources for, 137-143

second-generation, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f

strengths vs limitations of, 62t

third-generation, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f

Antibiotic therapies (*continued*)

clindamycin, 22-24, 22t, 185, 193-196, 194t-195t, 198, 201-202

clinical management and, 59-80

complications and, 201-208

contagion impacts and, 14

differential diagnoses and, 16-18, 18t

disease manifestations and, 11

duration criteria for, 157-176, 173f

for amoxicillin, 160t

for azalides and azithromycin, 161t-162t

bacteriologic eradication and, 157-165, 159t-163t

for cephalosporins, 160t-163t, 166t, 168f-171f

clinical trials and research studies of, 157-173

compliance and, 157-158, 173f

fundamentals of, 157-158

for penicillin, 157-158, 159t-163t, 166t

reference resources for, 167, 174-176

sensitivity analyses and, 166t

failure parameters, 84t, 145-196, 195t, 201-202

carriage and, 153-154, 195-196, 195t

clinical trials and research studies of, 145-154

coaggregation, 150-153, 152f

compliance, 146-147, 147t

copathogens, 150, 151f

early treatment, 148-149, 149t

exposures, repeated, 148

failure rates, 84t, 178-183, 201-202

formulation deficiencies, 145

fundamentals of, 145, 146t

immunity suppression, 148-149, 149t

microbial ecology alterations, 153

reference resources for, 154-156

strain differences, 154

guidelines for, 41-53, 82t-83t, 98-99, 196, 197t

AAP, 196, 197t

AHA, 82t-83t

IDSA, 41-53, 98-99, 196, 197t

ideal characteristics of, 61

impacts of, 193-195, 194t

lincomycin, 22-24, 22t, 185, 194-195, 194t

macrolides, 22-24, 22t, 91-118, 195-196, 195t

azalides and azithromycin, 22-24, 22t, 91-93, 92t, 98-110, 100t-102t,

104f-109f, 184

bacterial resistance and, 91-95, 92t

clarithromycin, 22-24, 22t, 92t, 93-94, 98, 100t-102t

clinical trials and research studies of, 91-95, 92t, 96t-97t, 100t-102t,

104f-109f

cure rates of, 104f-109f

erythromycin, 22-24, 22t, 82t-83t, 92t, 93-98, 96t-97t, 100t-102t, 184

extended-spectrum, 184

fundamentals of, 66t-68t, 91, 110

IDSA guidelines for, 98-99

ketolides and telithromycin, 92t, 94-95

penicillin allergies and, 91, 95-98, 96t-97t

Antibiotic therapies, macrolides (*continued*)

- reference resources for, 111-112
- strengths vs limitations of, 62t
- option overviews, 59-80
 - adherence and compliance, 63-65, 64t
 - appropriate selection, 61-62, 62t
 - clinical trials and research studies of, 59-77
 - cost-related factors, 76t-77t
 - cross allergic reactions, 65-75, 66t-68t, 73t-74t
 - diagnosis accuracy and, 61-62, 62t
 - efficacy factors, 76t-77t
 - fundamentals of, 59-61, 60t, 72, 76t-77t
 - reference resources for, 75, 78-79
 - tolerability factors, 76t-77t
- outcomes, 49-58
 - ARF primary prevention, 49-53, 50t-51t
 - bacteriologic eradication, 49-53, 50f, 50t-51t, 54t-55t
 - clinical trials and research studies of, 49-55
 - FDA and, 49
 - fundamentals of, 49-50, 50f, 50t-51t
 - guidelines for, 50t
 - reference resources for, 57-58
- penicillin and amoxicillin, 21-24, 22t, 81-90, 119-128, 193-195, 194t-195t, 201-202
 - AHA guidelines for, 82t-83t
 - amoxicillin, 21-24, 22t, 85-91, 88t, 100t-102t
 - amoxicillin-clavulanate, 89-91, 91, 100t-102t, 183-186
 - ampicillin, 85-89, 88t
 - benzathine penicillin G, 82t-83t, 84-85, 86t-87t, 184
 - benzathine penicillin plus rifampin, 194-195, 194t
 - vs cephalosporins, 119-128, 120t-125t, 126f-127f, 130t, 132t-133t, 135f-136f
 - clinical trials and research studies of, 81-89, 82t-84t, 86t-88t
 - vs cloxacillin, 89
 - complications and, 201-202
 - cost-related factors of, 89
 - vs dicloxacillin, 89
 - vs erythromycin, 82t-83t
 - failure rates of, 84t, 201-202
 - fundamentals of, 66t-68t, 81-84, 82t-84t
 - vs nafcillin, 89
 - penicillin, 21-24, 22t, 81-90, 119-128
 - penicillin allergies, 82t-83t, 91, 95-98, 96t-97t
 - penicillin G, 184
 - penicillin G, oral, 84-85, 86t-87t, 89
 - penicillin plus rifampin, 193-195, 194t
 - penicillin V, 82t-83t, 84-85, 86t-87t, 184-186
 - penicillin VK, 76t-77t
 - procaine penicillin, 84-85
 - recurrent infections and, 178-185
 - reference resources for, 89-90
 - strengths and limitations of, 62t
 - recurrent infections and, 178-183
 - rifampin, 194-195, 194t

Antibiotic therapies (*continued*)

- roxithromycin, 102t
- sulfadiazine, 21-22
- sulfonamides, 22t
- susceptibility, 21-28
- telithromycin, 22-24, 22t
- tetracyclines, 22t
- Antibody production, 202
- Antideoxyribonuclease B. *See* Anti-DNase B (antideoxyribonuclease B).
- Antigen detection tests, rapid, 14, 39-43, 40t-41t, 42f, 44t
- Antimicrobials. *See* Antibiotic therapies.
- Antistreptolysin O. *See* ASO (antistreptolysin O).
- Arcanobacterium haemolyticum*, 15-16, 16t, 18t
- ARF (acute rheumatic fever), 49-53, 50t-51t, 144, 193-197, 197t. *See also* Rheumatic fever.
- Arthritis, 201-202, 215-217
- ASO (antistreptolysin O), 202, 214
- Assays, *in vitro* vs *in vivo*, 216-217
- Asymptomatic carriage, 179, 193-195. *See also* Carriage.
- Attention deficit hyperactivity disorder. *See* ADHD (attention deficit hyperactivity disorder).
- Axetil. *See* Cefuroxime/cefuroxime axetil.
- Azalides and azithromycin, 22-24, 22t, 64t, 76t-77t, 91-100, 92t, 100t-102t, 104f-109f, 184. *See also* Macrolides.
- Bacteremia, 201-202
- Bacterial protein synthesis inhibition, 201-202
- Bacterial resistance, 91-95, 92t
- Bacteriocins, 178t
- Bacteriologic eradication, 49-53, 50f, 50t-51t, 54t-55t, 157-165, 159t-163t
- Bacteroides* spp., 179-180
- Basic concepts. *See* Fundamental concepts.
- BDQ (Becton Dickenson) rapid test, 41-43. *See also* RADTs (rapid antigen detection tests).
- Benzathine penicillin, 53, 54t-55t, 76t-77t, 82t-83t, 84-85, 86t-87t, 184, 194-195, 194t. *See also* Penicillin and amoxicillin.
 - G, 53, 54t-55t, 76t-77t, 82t-83t, 84-85, 86t-87t, 184
 - plus rifampin, 194-195, 194t
- β -Hemolytic streptococci, 37
- β -Lactams, 22-24, 22t, 91-92, 179-180, 202
- Bioinformatics analyses, 216-217
- BioStar (Accева) rapid tests, 41-43. *See also* RADTs (rapid antigen detection tests).
- Brain disease, 215-217
- Breese nine-factor probability estimator, 29-32, 32t-33t. *See also* Clinical diagnoses.
- C-5a peptidase, 216-217
- C-repeats (C-repeat peptides of M proteins), 214-215
- Carditis, 215-217
- Carriage, 193-200
 - antibiotic therapies and, 193-195, 194t-195t. *See also* Antibiotic therapies.
 - AAP guidelines, 196, 197t
 - benzathine penicillin plus rifampin, 194-195, 194t

Carriage, antibiotic therapies and (*continued*)

cefixime, 194-195, 194t
cefprozil, 193-195, 194t
cephalosporins, 195-196, 195t, 198
clindamycin, 193-196, 194t-195t, 198
failure parameters, 195-196, 195t
IDSA guidelines for, 196, 197t
impacts of, 193-195, 194t
lincomycin, 194-195, 194t
macrolides, 195-196, 195t
penicillin, 193-195, 194t-195t
penicillin plus rifampin, 193-195, 194t
rifampin, 194-195, 194t
asymptomatic, 193-195
chronic, 182-183. *See also* Recurrent infections.
clinical trials and research studies of, 196-198, 196t
contagion and, 196-198, 197t. *See also* Contagion.
definite vs possible, 197t
epidemiology and etiology of, 193-195, 194t
failure parameters and, 153-154, 195-196, 195t. *See also* Failure parameters.
fundamentals of, 193-195
post-treatment rates, 195-196, 195t
reference resources for, 198-200
Cavernous sinus thrombosis, 11
CDC (Centers for Disease Control and Prevention), 37
Cedax, 120t. *See also* Cefibuten.
Cefaclor, 22-24, 22t, 66t-68t, 73t-74t, 76t-77t, 100t-102t, 122t-125t, 128-137, 130t
Cefadroxil, 22-24, 22t, 66t-68t, 73t-74t, 76t-77t, 120t, 122t-125t, 128-137, 130t, 160t-161t
Cefamandole, 74t
Cefatrizine, 122t-124t
Cefazolin, 73t, 74t
Cefdinir, 22-24, 22t, 64t, 65, 68t, 72, 73t-74t, 76t-77t, 120t, 125t, 128-137, 130t, 135f-136f, 147t, 158, 160t-161t
Cefditoren, 120t
Cefepime, 73t, 74t
Cefetamet/cefetamet pivoxil, 124t, 128-137, 130t
Cefixime, 68t, 73t, 76t-77t, 120t, 125t, 128-137, 130t, 160t-161t, 194-195, 194t
Cefmetazole, 74t
Cefonicid, 73t-74t
Cefoperazone, 73t-74t
Cefotaxime, 73t-74t
Cefotetan, 73t-74t
Cefotiam, 160t-161t
Cefoxitin, 74t
Cefpodoxime/cefepodoxime proxetil, 22-24, 22t, 120t, 122t-125t, 128-137, 130t, 160t-161t
Cefprozil, 22-24, 22t, 66t-68t, 73t, 76t-77t, 120t, 124t-125t, 128-137, 130t, 193-195, 194t
Cefsulodin, 74t
Ceftazidime, 74t
Ceftibuten, 22-24, 22t, 73t-74t, 76t-77t, 120t, 124t-125t, 128-137, 130t

Ceftin, 120t. *See also* Cefuroxime/cefuroxime axetil.

Ceftriaxone, 22-24, 22t, 74t
Cefuroxime/cefuroxime axetil, 22-24, 22t, 64t, 66t-68t, 73t-74t, 76t-77t, 120t, 124t-125t, 128-137, 130t, 160t-161t
Cefzil, 120t. *See also* Cefprozil.
Cell invasiveness, 94-95
Cellulitis, 201-202
Centers for Disease Control and Prevention. *See* CDC (Centers for Disease Control and Prevention).
Cephalexin, 22-24, 22t, 66t-68t, 74t, 76t-77t, 120t, 122t-125t, 128-137, 130t
Cephaloglycin, 122t-125t, 128-137
Cephalosporins, 22-24, 22t, 91, 119-144, 122t-125t, 130t, 135f-136f, 195-196, 195t, 198, 204-205. *See also under individual drug names.*
carriage and, 195-196, 195t, 198. *See also* Carriage.
cefaclor, 22-24, 22t, 100t-102t, 122t-125t, 128-137, 130t
cefadroxil, 22-24, 22t, 120t, 122t-125t, 128-137, 130t, 160t-161t
cefatrizine, 122t-124t
cefdinir, 22-24, 22t, 64t, 65, 68t, 72, 73t-74t, 76t-77t, 120t, 125t, 128-137, 130t, 135f-136f, 147t, 158, 160t-161t
cefditoren, 120t
cefetamet/cefetamet pivoxil, 124t, 128-137, 130t
cefixime, 120t, 125t, 128-137, 130t, 160t-161t, 194-195, 194t
cefotiam, 160t-161t
cefepodoxime/cefepodoxime proxetil, 22-24, 22t, 120t, 122t-125t, 128-137, 130t, 160t-161t
cefprozil, 22-24, 22t, 120t, 124t-125t, 128-137, 130t, 193-195, 194t
ceftibuten, 22-24, 22t, 120t, 124t-125t, 128-137, 130t
ceftriaxone, 22-24, 22t
cefuroxime, 160t-161t
cefuroxime/cefuroxime axetil, 22-24, 22t, 120t, 124t-125t, 128-137, 130t
cephalexin, 22-24, 22t, 120t, 122t-125t, 128-137, 130t
cephaloglycin, 122t-125t, 128-137
cephradine, 120t
chemical structure of, 73t
vs ciprofloxacin, 22-24, 22t
clinical trials and research studies of, 119-137, 120t-125t, 126f-127f, 130t, 132t-133t, 135f-136f
complications and, 204-205
duration criteria for, 160t-163t, 166t. *See also* Duration criteria.
first-generation, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f
fundamentals of, 66t-68t, 119-128, 120t-125t, 126f-127f, 134-137
loracarbef, 120t, 124t-125t, 128-137, 130t
vs macrolides, 91. *See also* Macrolides.
vs penicillin, 119-128, 120t-125t, 126f-127f, 130t, 132t-133t, 135f-136f.
See also Penicillin and amoxicillin.
recurrent infections and, 183-185
reference resources for, 137-143
second-generation, 91, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f
sensitivity analyses of, 132t-133t
stratified analyses of, 128-135, 130t, 132t-133t, 135f-136f
strengths and limitations of, 62t
third-generation, 91, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f
Cephalothin, 74t
Cephapirin, 73t-74t

- Cephadrine, 73t-74t, 120t
 Cervical adenitis, 201-202
 Cervical lymphadenitis, 31
Chlamydia pneumoniae, 15-16, 16t, 18t
 Chorea, 215-217
 Choreiform finger movements, 204
 Chronic streptococcal carriage, 182-183
 Ciprofloxacin, 22-24, 22t
 Clarithromycin, 22-24, 22t, 64t, 76t-77t, 92t, 93-94, 98, 100t-102t. *See also* Macrolides.
 Clavulanate. *See* Amoxicillin and penicillin.
 CLIA regulations, 39
 Clindamycin, 22-24, 22t, 185, 193-196, 194t-195t, 198, 201-202
 Clinical diagnoses, 29-36. *See also* Diagnoses.
 Breese nine-factor probability estimator, 29-32, 32t-33t
 clinical and epidemiological findings, 29-30, 31t
 fundamentals of, 29
 McIsaac scores, 31, 34t
 reference resources for, 35-36
 Wald scores, 29-31, 34t
 Clinical management-related concepts (streptococcal pharyngitis). *See also* *under individual topics*.
 antibiotic therapies, 49-176
 cephalosporins, 119-144
 duration criteria, 157-176
 failure parameters, 145-156
 macrolides, 91-118
 option overviews, 59-80
 outcomes, 49-58
 penicillin and amoxicillin, 81-90
 susceptibility, 21-28
 carriage, 193-200
 complications, 201-212
 contagion, 13-14
 diagnoses, 15-20, 29-48
 clinical, 29-36
 differential, 15-20
 laboratory, 37-48
 disease manifestations, 11-12
 fundamentals. *See* Fundamental concepts.
 prevention, 213-218
 recurrent infections, 177-192
 reference resources. *See* Reference resources.
 Clinical trials and research studies. *See also under individual topics*.
 of antibiotic therapies, 49-55, 59-77, 81-89, 82t-84t, 86t-88t, 91-95, 92t, 96t-97t, 100t-102t, 104f-109f, 119-137, 120t-125t, 126f-127f, 130t, 132t-133t, 135f-136f, 145-154, 157-173
 cephalosporins, 119-137, 120t-125t, 126f-127f, 130t, 132t-133t, 135f-136f
 duration criteria, 157-173
 failure parameters, 145-154
 macrolides, 91-95, 92t, 96t-97t, 100t-102t, 104f-109f
 option overviews, 59-77
 outcomes, 49-55
 penicillin and amoxicillin, 81-89, 82t-84t, 86t-88t
 Clinical trials and research studies (*continued*)
 of carriage, 196-198, 196t
 of diagnoses, 16-17, 29-34, 38-46, 40t-41t
 clinical, 29-34
 differential, 16-17
 laboratory, 38-46, 40t-41t
 of recurrent infections, 177-186
 of susceptibility, 21-24
 Cloxacillin, 89
 Coaggregation, 150-153, 152f, 178t
 Colitis, pseudomembranous, 194-195
 Compliance, 146-147, 147t, 157-158, 173f
 duration criteria and, 157-158, 173f
 failure parameters and, 146-147, 147t
 Compliance and adherence, 63-65, 64t
 Complications, 201-212
 antibiotic therapy responses and, 208
 case study for, 204-205
 fundamentals of, 209
 nonsuppurative, 202
 OCD, 203-208, 206t-207t
 PANDAS, 203-209, 205t-206t
 reference resources for, 209-211
 suppurative, 201-202
 Compulsive daytime urinary urgency, 204-205
 Compulsive handwashing, 204, 206t-207t
 Conjunctivitis, 30t
 Contagion, 13-14, 14f
 antibiotic treatment impacts, 14
 carriage and, 196-198, 197t. *See also* Carriage.
 in day care centers and schools, 13
 direct contact, 13
 false-negative test results, 14
 in families, 13-14, 14f
 fundamentals of, 14
 GAS, 13-14, 14f
 GAS tonsillopharyngitis, 14
 person-to-person, 13-14
 rapid GAS antigen detection tests, 14
 Copathogens, 150-151f, 151f, 178t, 194-195. *See also* Pathogens.
Corynebacterium diphtheriae, 15, 16t
 Coryza, 30t
 Cost-related factors, 76t-77t, 89
 Cough, absence of, 29-30, 31t
 Cross allergic reactions, 65-75, 66t-68t, 73t-74t
 Cross-reactive antibodies, 73t, 214-215
 Cultures, throat. *See* Throat cultures.
 Cure rates, macrolides, 104f-109f
 Cytokine profiles, 216-217
 Day care center contagion issues, 13. *See also* Contagion.
 Daytime urinary urgency, compulsive, 204-205
 De novo stimulation, human T lymphocytes, 214-215
 Definite vs possible carriage, 197t. *See also* Carriage.

- Detection tests, rapid, 14, 39-43, 40t-41t, 42f, 44t
- Diagnoses, 15-20, 29-48. *See also under individual topics.*
 accuracy of, 61-62, 62t
 clinical, 29-36
 Breese nine-factor probability estimator, 29-32, 32t-33t
 clinical trials and research studies of, 29-34
 findings, clinical and epidemiological, 29-30, 31t
 fundamentals of, 29
 McIsaac scores, 31, 34t
 reference resources for, 35-36
 Wald scores, 29-31, 34t
 differential, 15-20
 antibiotic therapies and, 16-18, 18t
 causative factors and agents, 15-16, 16t, 17f
 clinical trials and research studies of, 16-17
 epidemiology and etiology, 15-16, 16t, 17f
 fundamentals of, 15
 pathogens and, 15-20, 16t, 17f
 reference resources for, 18-19
 laboratory, 37-48
 Abbot Labs (Signify), 41-43
 Becton Dickenson (BDQ), 41-43
 BioStar (Acceava), 41-43
 CDC and, 37
 CLIA regulations and, 39
 clinical trials and research studies of, 38-46, 40t-41t
 fundamentals of, 37, 44t
 IDSA guidelines and, 41-53
 longitudinal care and, 43-45
 RADTs, 39-43, 40t-41t, 42f, 44t
 throat cultures, 37-39, 44t
- Diarrhea, 30t
- Dicloxacillin, 89
- Differential diagnoses, 15-20. *See also* Diagnoses.
 antibiotic therapies and, 16-18, 18t
 causative factors and agents, 15-16, 16t, 17f
 epidemiology and etiology, 15-16, 16t, 17f
 fundamentals of, 15
 pathogens and, 15-20, 16t, 17f. *See also* Pathogens.
Arcanobacterium haemolyticum, 15-16, 16t, 18t
Chlamydia pneumoniae, 15-16, 16t, 18t
Corynebacterium diphtheriae, 15, 16t
Haemophilus influenzae, 15, 16t
Haemophilus parainfluenzae, 18t
Mycoplasma pneumoniae, 15-16, 16t, 18t
Neisseria gonorrhoeae, 15, 16t
Staphylococcus aureus, 15, 16t, 18t
Streptococcus (GAS), 15-20, 16t, 18t
Streptococcus (groups C, G, and F), 15-20, 16t, 18t
 treat vs do not treat, 18t
 reference resources for, 18-19
- Disease manifestations, 11-12, 12f
 antibiotic treatment impacts, 11
 fundamentals of, 11-12, 12f
- Disease manifestations (*continued*)
 infection transfer parameters, 11
 PANDAS, 11-12, 12f
 pathologic changes, 11
- Dogs as carriers, 177-178, 178t
- Drug consumption, 94-95
- Duration criteria, 157-176, 173f
 for amoxicillin, 160t
 for azalides and azithromycin, 161t-162t
 bacteriologic eradication and, 157-165, 159t-163t
 for cephalosporins, 160t-163t, 166t, 168f-171f
 cefadroxil, 160t-161t
 cefdinir, 160t-161t
 cefixime, 160t-161t
 cefotiam, 160t-161t
 cefepoxime, 160t-161t
 cefuroxime, 160t-161t
 clinical trials and research studies of, 157-173
 compliance and, 157-158, 173f
 fundamentals of, 157-158
 for penicillin, 157-158, 159t-163t, 166t
 reference resources for, 167, 174-176
 sensitivity analyses and, 166t
- Duricef, 120t. *See also* Cefadroxil.
- Dysuria, 204-205
- Eagle effect, 23-24, 201-202
- Early treatment as failure parameter, 148-149, 149t
- Ecology alterations, microbial, 153
- Edema, 11
- Efficacy factors, 76t-77t
- Elevated WBC (white blood cell) counts, 29-30, 31t
- End-organ damage, 202
- Enterobacteriaceae, 94
- Enzyme-linked immunosorbent assay antibodies, 214-215
- Epidemics, 23-24
- Epidemiology and etiology, 15-16, 16t, 17f, 193-195, 194t
- Epitopes, 215-217
- Eradication, bacteriologic, 49-53, 50f, 50t-51t, 54t-55t, 157-165, 159t-163t
- Erms* genes, 93-94
- Erysipelas, 11
- Erythema, 11
- Erythromycin, 22-24, 22t, 66t-68t, 76t-77t, 82t-83t, 92t, 93-98, 96t-97t, 100t-102t, 184. *See also* Macrolides.
- Estimators and scores. *See* Clinical diagnoses.
- Etiology and epidemiology, 15-16, 16t, 17f
- Exposures, repeated, 148, 179
- Extended-release (XL) clarithromycin filmtabs, 98
- Extended-spectrum macrolides, 184. *See also* Macrolides.
- Failure parameters, 84t, 145-196, 195t, 201-202
 carriage and, 153-154, 195-196, 195t. *See also* Carriage.
 clinical trials and research studies of, 145-154
 coaggregation, 150-153, 152f

- Failure parameters (*continued*)
 compliance, 146-147, 147t. *See also* Compliance.
 copathogens, 150, 151f
 early treatment, 148-149, 149t
 exposures, repeated, 148
 failure rates, 84t, 178-183, 201-202
 formulation deficiencies, 145
 fundamentals of, 145, 146t
 immunity suppression, 148-149, 149t
 microbial ecology alterations, 153
 recurrent infections and, 178-183
 reference resources for, 154-156
 strain differences, 154
- False-negative vs false-positive cultures, 14, 37-39. *See also* Throat cultures.
- Family contagion issues, 13-14, 14f. *See also* Contagion.
- Family pets as carriers, 177-178, 178t
- Fasciitis, 201-202
- FDA (Food and Drug Administration), 49, 81
- Fever, 29-30, 31t
- Fibronectin-binding proteins, 216-217
- Fidgeting, 204
- Findings, clinical and epidemiological, 29-30, 31t. *See also* Clinical diagnoses.
- First-generation cephalosporins, 66t-68t, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f. *See also* Cephalosporins.
- First-generation rapid antigen detection tests, 39-43, 40t-41t, 42f. *See also* RADTs (rapid antigen detection tests).
- Food and Drug Administration. *See* FDA (Food and Drug Administration).
- Formulation deficiencies, 145
- Fundamental concepts. *See also under individual topics.*
 for antibiotic therapies, 49-50, 50f, 50t-51t, 81-84, 82t-84t, 91, 110, 119-128, 120t-125t, 126f-127f, 134-137, 157-158
 cephalosporins, 119-128, 120t-125t, 126f-127f, 134-137
 duration criteria, 157-158
 failure parameters, 145, 146t
 macrolides, 91, 110
 outcomes, 49-50, 50f, 50t-51t
 penicillin and amoxicillin, 81-84, 82t-84t
 for carriage, 193-195
 for complications, 209
 for contagion, 14
 for diagnoses, 15, 29, 37, 44t
 clinical, 29
 differential, 15
 laboratory, 37, 44t
 for disease manifestations, 11
 for prevention, 213
 for recurrent infections, 177
 for susceptibility, 21
- Fusobacterium* spp, 179-180
- GAS (group A streptococcal) infection concepts. *See also under individual topics.*
 antibiotic therapies, 49-176
 cephalosporins, 119-144
 duration criteria, 157-176
 failure parameters, 145-156
 macrolides, 91-118
 option overviews, 59-80
 outcomes, 49-58
 penicillin and amoxicillin, 81-90
 susceptibility, 21-28
 carriage, 193-200
 complications, 201-212
 contagion, 13-14
 diagnoses, 15-20, 29-48
 clinical, 29-36
 differential, 15-20
 laboratory, 37-48
 disease manifestations, 11-12
 fundamentals. *See* Fundamental concepts.
 prevention, 213-218
 recurrent infections, 177-192
 reference resources. *See* Reference resources.
- GAS-mediated necrotizing fasciitis, 198, 201-202
- GAS toxic shock syndrome, 23-24, 198, 201-202
- Germ hoarding, 206t-207t
- Glomerulonephritis, post-streptococcal, 12f
- Group A streptococcal infection concepts. *See* GAS (group A streptococcal) infection concepts.
- Guidelines, 41-53, 50t, 82t-83t, 107t, 196
 AAP, 50t, 196, 197t
 AHA, 50t, 82t-83t
 American Academy of Family Physicians, 50t
 IDSA, 41-53, 50t, 196, 197t
- Haemophilus influenzae*, 15, 16t, 179-180
- Haemophilus parainfluenzae*, 18t, 179-180
- Handwashing, compulsive, 204, 206t-207t
- Handwriting deterioration, 204
- Hemolytic streptococci, *a-* vs *B-*, 37, 94, 180-181
- Historical perspectives, 37, 213-214
 of throat cultures, 37
 of vaccination, 213-214
- Human T lymphocytes, *de novo* stimulation, 214-215
- Hyperactivity, 204-207, 206t-207t
- IDSA (Infectious Disease Society of America) guidelines, 41-53, 50t, 98-99, 196, 197t
- IgA (immunoglobulin A), 216-217
- IgE (immunoglobulin E), 72
- Immunity, antibiotic suppression of, 148-149, 149t, 180-181
- Immunoglobulin, 72, 216-217
 IgA, 216-217
 IgE, 72

- In vitro* vs *in vivo* assays, 216-217
- Infection transfers, 11
- Infectious Disease Society of America. *See* IDSA (Infectious Disease Society of America) guidelines.
- Inflammatory processes, 11-12, 12f
- Inhibition, adherence, 216-217
- Intercurrent viral pharyngitis, 195-196
- Interferon γ , 216-217
- Interleukin-4, 216-217
- Intestinal enterococci, 94
- Introductory concepts. *See* Fundamental concepts.
- Invasiveness, cell, 94-95
- Joint disease, 215-217
- Keflex, 120t. *See also* Cephalexin.
- Ketolides and telithromycin, 92t, 94-95
- Laboratory diagnoses, 37-48. *See also* Diagnoses.
- CDC and, 37
 - CLIA regulations and, 39
 - clinical trials and research studies of, 38-46, 40t-41t
 - fundamentals of, 37, 44t
 - IDSA guidelines and, 41-53
 - longitudinal care and, 43-45
 - RADTs, 39-43, 40t-41t, 42f, 44t
 - Abbot Labs (Signify), 41-43
 - Becton Dickenson (BDQ), 41-43
 - BioStar (Acceava), 41-43
 - throat cultures, 37-39
 - false-negative, 38-39
 - false-positive, 37
 - historical perspectives of, 37
- Leukocyte migration exudates, 11-12, 12f
- Lincomycin, 22-24, 22t, 185, 194-195, 194t
- Lipoprotein candidate antigens, 216-217
- Longitudinal care, 43-45
- Lorabid, 120t. *See also* Loracarbef.
- Loracarbef, 76t-77t, 120t, 124t-125t, 128-137, 130t
- M proteins, C-repeat peptides, 214-215
- M-type vaccination, 213-217. *See also* Vaccination.
- Macrolides, 66t-68t, 91-118, 92t, 93-98, 96t-97t, 100t-102t, 195-196, 195t
- azalides and azithromycin, 22-24, 22t, 91-93, 92t, 98-110, 100t-102t, 104f-109f, 184
 - bacterial resistance and, 91-95, 92t
 - amoxicillin-clavulanate and, 91, 100t-102t
 - β -lactams and, 91-92
 - cefaclor and, 100t-102t
 - cell invasiveness and, 94-95
 - drug consumption and, 94-95
 - erm*s genes and, 93-94
 - mef* genes and, 93-94
 - MLS_B resistance phenotype, 93-94
 - Macrolides, bacterial resistance and (*continued*)
 - penicillin and, 100t-102t
 - penicillin V and, 95, 98, 100t-102t
 - roxithromycin and, 102t
 - Streptococcus pyogenes*, 91-95
 - target-site modification, 93-94
 - vs cephalosporins, 91. *See also* Cephalosporins.
 - clarithromycin, 22-24, 22t, 92t, 93-94, 98, 100t-102t
 - clinical trials and research studies of, 91-95, 92t, 96t-97t, 100t-102t, 104f-109f
 - cure rates of, 104f-109f
 - erythromycin, 22-24, 22t, 82t-83t, 92t, 93-98, 96t-97t, 100t-102t, 184
 - extended-spectrum, 184
 - fundamentals of, 66t-68t, 91, 110
 - IDSA guidelines for, 98-99
 - ketolides and telithromycin, 22-24, 22t, 92t, 94-95
 - lincomycin and, 22-24, 22t
 - penicillin allergies and, 91, 95-98, 96t-97t
 - reference resources for, 111-112
 - strengths and limitations of, 62t
- Management-related concepts (streptococcal pharyngitis). *See also under individual topics.*
- antibiotic therapies, 49-176
 - cephalosporins, 119-144
 - duration criteria, 157-176
 - failure parameters, 145-156
 - macrolides, 91-118
 - option overviews, 59-80
 - outcomes, 49-58
 - penicillin and amoxicillin, 81-90
 - susceptibility, 21-28
 - carriage, 193-200
 - complications, 201-212
 - contagion, 13-14
 - diagnoses, 15-20, 29-48
 - clinical, 29-36
 - differential, 15-20
 - laboratory, 37-48
 - disease manifestations, 11-12
 - fundamentals. *See* Fundamental concepts.
 - prevention, 213-218
 - recurrent infections, 177-192
 - reference resources. *See* Reference resources.
- Manifestations of disease, 11-12
- Mastoiditis, 11
- MBCs (minimum bacterial concentrations), 23-24
- McIsaac scores, 31, 34t. *See also* Clinical diagnoses.
- Memory impairments, 204
- Meningitis, 11, 201-202
- Microbial ecology alterations, 153
- MICs (minimum inhibitory concentrations), 21-22, 22t
- Migration exudates, leukocyte, 11-12, 12f
- Minimally symptomatic carriage, 179

- Minimum bacterial concentrations. *See* MBCs (minimum bacterial concentrations).
- Minimum inhibitory concentrations. *See* MICs (minimum inhibitory concentrations).
- MLS_B (macrolide-lincosamide-streptogramin_B) resistance phenotype, 93-94. *See also* Macrolides.
- Moraxella catarrhalis*, 178t, 179-180
- Moxalactam, 73t
- Mycoplasma pneumoniae*, 15-16, 16t, 18t
- Myositis, 198
- Nafcillin, 89
- Nausea, 30t, 186
- Necrotizing fasciitis, GAS-mediated, 198, 201-202
- Neisseria gonorrhoeae*, 15, 16t
- Nephritis, 202, 215-217
- Neuropsychiatric symptoms, 204
- Nine-factor probability estimator, 29-32, 32t-33t
- Nonsuppurative complications, 202. *See also* Complications.
- OCD (obsessive-compulsive disorder), 203-208, 206t-207t. *See also* Complications.
- Omnicef, 120t. *See also* Cefdinir.
- Opacity factors, serum, 216-217
- Opsonic antibodies, 216-217
- Option overviews, 59-80. *See also* Antibiotic therapies.
- adherence and compliance, 63-65, 64t
 - appropriate antibiotic selection, 61-62, 62t
 - clinical trials and research studies of, 59-77
 - cost-related factors, 76t-77t
 - cross allergic reactions, 65-75, 66t-68t, 73t-74t
 - diagnosis accuracy and, 61-62, 62t
 - efficacy factors, 76t-77t
 - fundamentals of, 59-61, 60t, 72, 76t-77t
 - reference resources for, 75, 78-79
 - tolerability factors, 76t-77t
- Oral cephalosporins. *See* Cephalosporins.
- Oral penicillin G, 84-85, 86t-87t, 89. *See also* Penicillin and amoxicillin.
- Orthodontic appliance contamination, 178t
- Osteomyelitis, 11, 201-202
- Otitis media, 85
- Outcomes, 49-58. *See also* Antibiotic therapies.
- ARF primary prevention, 49-53, 50t-51t
 - bacteriologic eradication, 49-53, 50f, 50t-51t, 54t-55t
 - clinical trials and research studies of, 49-55
 - FDA and, 49
 - fundamentals of, 49-50, 50f, 50t-51t
 - guidelines for, 50t. *See also* Guidelines.
 - reference resources for, 57-58
- Overviews and summaries. *See* Fundamental concepts.
- PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococci), 11-12, 12f, 203-209, 205t-206t, 215-217. *See also* Complications.
- Pathogens, 15-20, 16t, 17f, 150, 150f-151f, 154, 178t, 194-195. *See also* under individual pathogens.
- Arcanobacterium haemolyticum*, 15-16, 16t, 18t
 - Chlamydia pneumoniae*, 15-16, 16t, 18t
 - copathogens, 150, 150f-151f, 178t, 194-195
 - Corynebacterium diphtheriae*, 15, 16t
 - Fusobacterium* spp, 179-180
 - Haemophilus influenzae*, 15, 16t, 179-180
 - Haemophilus parainfluenzae*, 18t, 179-180
 - laboratory diagnoses and, 37-48. *See also* Laboratory diagnoses.
 - Moraxella catarrhalis*, 178t, 179-180
 - Mycoplasma pneumoniae*, 15-16, 16t, 18t
 - Neisseria gonorrhoeae*, 15, 16t
 - Staphylococcus aureus*, 15, 16t, 18t, 23-24, 37, 179-180
 - strain differences, 154
 - Streptococcus* spp, 15-20, 91-95
 - Streptococcus* (GAS), 15-20, 16t, 18t
 - Streptococcus* (groups C, G, and F), 15-20, 16t, 18t
 - Streptococcus pyogenes*, 91-95
- Pathologic changes, 11
- Patient compliance and adherence, 63-65, 64t, 146-147, 147t, 157-158, 173f
- adherence factors, 63-65, 64t
 - duration criteria and, 157-158, 173f
 - failure parameters and, 146-147, 147t
- Pediatric autoimmune neuropsychiatric disorder associated with streptococci. *See* PANDAS (pediatric autoimmune neuropsychiatric disorder associated with streptococci).
- Penicillin and amoxicillin, 21-24, 22t, 66t-68t, 76t-77t, 81-90, 119-128, 193-195, 194t-195t, 201-202. *See also* Antibiotic therapies.
- AHA guidelines for, 82t-83t
 - amoxicillin, 21-24, 22t, 85-91, 88t, 100t-102t
 - amoxicillin-clavulanate, 64t, 76t-77t, 89-91, 100t-102t, 183-186
 - vs ampicillin, 85-89, 88t
 - vs cephalosporins, 119-128, 120t-125t, 126f-127f, 130t, 132t-133t, 135f-136f. *See also* Cephalosporins.
 - chemical structure of, 73t
 - clinical trials and research studies of, 81-89, 82t-84t, 86t-88t
 - vs cloxacillin, 89
 - complications and, 201-202
 - cost-related factors of, 89
 - vs dicloxacillin, 89
 - failure rates of, 84t, 201-202
 - fundamentals of, 66t-68t, 81-84, 82t-84t
 - vs nafcillin, 89
 - nonsuppurative complications and, 202
 - penicillin, 21-24, 22t, 49, 76t-77t, 81-98, 82t-83t, 86t-87t, 96t-97t, 119-128, 184, 193-195, 194t
 - allergies, 82t-83t, 91, 95-98, 96t-97t
 - benzathine penicillin G, 82t-83t, 84-85, 86t-87t, 184
 - benzathine penicillin plus rifampin, 194-195, 194t
 - penicillin G, oral, 84-85, 86t-87t, 89
 - penicillin plus rifampin, 193-195, 194t
 - penicillin V, 82t-83t, 84-85, 86t-87t, 184-186

- Penicillin and amoxicillin, penicillin (*continued*)
- penicillin VK, 76t-77t
 - procaine penicillin, 84-85
 - recurrent infections and, 178-185. *See also* Recurrent infections.
 - reference resources for, 89-90
 - strengths and limitations of, 62t
- Peptides, C-repeats, 214-215
- Peritonitis, 201-202
- Peritonsillar abscess, 15, 201-202
- Person-to-person contagion, 13-14. *See also* Contagion.
- Pets as carriers, 177-178, 178t
- Pharyngeal microflora, protective, 180
- Pharyngitis (streptococcal) clinical management concepts. *See also under individual topics.*
- antibiotic therapies, 49-176
 - cephalosporins, 119-144
 - duration criteria, 157-176
 - failure parameters, 145-156
 - macrolides, 91-118
 - option overviews, 59-80
 - outcomes, 49-58
 - penicillin and amoxicillin, 81-90
 - susceptibility, 21-28
- carriage, 193-200
- complications, 201-212
- contagion, 13-14
- diagnoses, 15-20, 29-48
- clinical, 29-36
 - differential, 15-20
 - laboratory, 37-48
- disease manifestations, 11-12
- fundamentals. *See* Fundamental concepts.
- prevention, 213-218
- recurrent infections, 177-192
- reference resources. *See* Reference resources.
- Phenoxymethyl penicillin (penicillin V), 82t-83t, 84-85, 86t-87t. *See also* Penicillin and amoxicillin.
- Ping-pong spread, 197t
- Pivoxil. *See* Cefetamet/cefetamet pivoxil.
- Pneumonia, 201-202
- Possible vs definite carriage, 197t. *See also* Carriage.
- Post-streptococcal glomerulonephritis, 12f, 202, 214-215
- Post-treatment rates, carriage, 195-196, 195t. *See also* Carriage.
- Prevention, 213-218
- fundamentals of, 213
 - reference resources for, 217-218
 - surgical intervention (tonsillectomy), 213
 - vaccination, 213-217
 - ASO titers, 214
 - C-repeats, 214-215
 - historical perspectives of, 213-214
 - lipoprotein candidate antigens, 216-217
 - M-types, 213-217
 - regulatory challenges for, 217
- Prevention, vaccination (*continued*)
- safety assessments of, 217
 - screening and, 215
 - in vitro* vs *in vivo* assays, 216-217
- Primary prevention, ARF (acute rheumatic fever), 49-53, 50t-51t
- Probability estimators and scores. *See* Clinical diagnoses.
- Procaine penicillin, 54t-55t, 84-85
- Protective pharyngeal microflora, eradication of, 180
- Protein synthesis inhibition, bacterial, 201-202
- Proxetil. *See* Cefpodoxime/cefepodoxime proxetil.
- Pseudomembranous colitis, 185, 194-195
- Pyoderma, 11
- RADTs (rapid antigen detection tests), 14, 39-43, 40t-41t, 42f, 44t
- Recurrent infections, 177-192
- antibiotic therapies for, 183-186. *See also* Antibiotic therapies.
 - amoxicillin-clavulanate, 183-186
 - azithromycin, 184
 - benzathine penicillin G, 184
 - cephalosporins, 183-185
 - clindamycin, 185
 - erythromycin, 184
 - lincomycin, 185
 - macrolides, 184
 - penicillin, 178-185
 - penicillin allergies and, 185
 - penicillin G, 184
 - penicillin V, 184-186
- clinical trials and research studies for, 177-186
- failure parameters, 178-183
- antibiotic failures, 178-183, 178t
 - carriage and, 178
 - compliance, lack of, 178-179
 - definitions of, 177
 - exposures, repeated, 179
 - immunity, antibiotic suppression of, 180-181
 - penicillin tolerance, 181-182
 - protective pharyngeal microflora, eradication of, 180
 - streptococcal carriage, chronic, 182-183
- fundamentals of, 177
- reference resources for, 187-191
- Recurrent ties, 204, 206t-207t
- Reference resources. *See also under individual topics.*
- for antibiotic therapies, 57-58, 89-90, 111-112, 137-143, 154-156, 167, 174-176
 - cephalosporins, 137-143
 - duration criteria, 167, 174-176
 - failure parameters, 154-156
 - macrolides, 111-112
 - outcomes, 57-58
 - penicillin and amoxicillin, 89-90
 - for carriage, 198-200
 - for complications, 209-211

- Reference resources (*continued*)
 for diagnoses, 18-19, 35-36
 clinical, 35-36
 differential, 18-19
 for prevention, 217-218
 for recurrent infections, 187-191
 for susceptibility, 24-28
- Regulatory challenges, vaccination, 217
- Relapses. *See* Recurrent infections.
- Renal disease, 215-217
- Repeated exposures, 148, 179
- Research studies. *See* Clinical trials and research studies.
- Retropharyngeal abscesses, 15
- Rheumatic fever, 16, 21-22, 82t-83t, 177, 202, 213-217. *See also* ARF (acute rheumatic fever).
- Rheumatic heart disease, 215-217
- Rhinorrhea, absence of, 29-30, 31t
- Rifampin, 193-195, 194t
 benzathine penicillin plus rifampin, 194-195, 194t
 penicillin plus rifampin, 193-195, 194t
- Roxithromycin, 102t
- Safety assessments, vaccination, 217
- Scarlatina rash, 16
- School contagion issues, 13. *See also* Contagion.
- Scores and probability estimators. *See* Clinical diagnoses.
- Screening, 215
- Second-generation cephalosporins, 66t-68t, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f. *See also* Cephalosporins.
- Second-generation RADTs (rapid antigen detection tests), 39-43, 40t-41t, 42f. *See also* RADTs (rapid antigen detection tests).
- Sensitivity analyses, 132t-133t, 166t
- Sentinel episodes, OCD, 208
- Separation anxiety, age-inappropriate, 204-205, 206t-207t
- Serum antibody production, 202
- Serum opacity factors, 216-217
- Signify (Abbot Labs), 41-43
- Sinus thrombosis, cavernous, 11
- Spectracef, 120t. *See also* Cefditoren.
- Staphylococcus aureus*, 15, 16t, 18t, 23-24, 37, 179-180, 194-195
- Stationary phase, 201-202
- Strain differences, 154
- Stratified analyses, 128-135, 130t, 132t-133t, 135f-136f
- Streptococcal pharyngitis (clinical management) concepts. *See also under individual topics.*
 antibiotic treatments, 49-176
 cephalosporins, 119-144
 duration criteria, 157-176
 failure parameters, 145-156
 macrolides, 91-118
 option overviews, 59-80
 outcomes, 49-58
 penicillin and amoxicillin, 81-90
 susceptibility, 21-28
- Streptococcal pharyngitis (clinical management) concepts (*continued*)
 carriage, 193-200
 complications, 201-212
 contagion, 13-14
 diagnoses, 15-20, 29-48
 clinical, 29-36
 differential, 15-20
 laboratory, 37-48
 disease manifestations, 11-12
 fundamentals. *See* Fundamental concepts.
 prevention, 213-218
 recurrent infections, 177-192
 reference resources. *See* Reference resources.
- Streptococcus* spp, 15-20, 91-95
 Streptococcus group A, 15-20. *See also* GAS (group A streptococcal) infection concepts.
 Streptococcus groups C, G, and F, 15-20, 16t, 18t
 Streptococcus pyogenes, 91-95
- Studies. *See* Clinical trials and research studies.
- Summaries. *See* Fundamental concepts.
- Super antigens, 216-217
- Suppressed immunity, 148-149, 149t, 180-181
- Suppurative complications, 201-202. *See also* Complications.
- Supraglottitis, 201-202
- Suprax, 120t. *See also* Cefixime.
- Surgical interventions, 213
- Susceptibility, 21-28
 to azithromycin, 21-24, 22t
 to clarithromycin, 21-24, 22t
 to clindamycin, 21-24, 22t
 clinical trials and research studies of, 21-24
 eagle effect and, 23-24
 to erythromycin, 21-24, 22t
 fundamentals of, 21
 to lincomycin, 21-24
 MBCs and, 23-24
 MICs and, 21-22, 22t
 reference resources for, 24-28
 resistance and, 21-24, 22t
- Sydenham chorea, 202-204
- T lymphocytes (human), de novo stimulation, 214-215
- Target-site modification, 93-94
- Telithromycin and ketolidides, 22-24, 22t, 92t, 94-95. *See also* Macrolides.
- Tetracyclines, 22t
- Therapies, antibiotic. *See* Antibiotic therapies.
- Third-generation cephalosporins, 68t, 120t, 125t, 128-135, 130t, 132t-133t, 135f-136f. *See also* Cephalosporins.
- Throat cultures, 37-39. *See also* Laboratory diagnoses.
 false-negative, 38-39
 false-positive, 37
 historical perspectives of, 37
- Thrombosis, sinus, 11
- Thyroiditis, 201-202

Tics, recurrent, 204, 206t-207t
Tolerability factors, 76t-77t
Tonsillectomy, 213
Toothbrush contamination, 178t
Toxic shock syndrome, GAS, 23-24, 198, 201-202
Transfer parameters, 11
Treatments, antibiotic. *See* Antibiotic therapies.
Trials. *See* Clinical trials and research studies.

US CDC (Centers for Disease Control and Prevention), 37
US FDA (Food and Drug Administration), 49, 81

Vaccination, 213-217. *See also* Prevention.
ASO titers, 214
C-repeats, 214-215
historical perspectives of, 213-214
lipoprotein candidate antigens, 216-217
M-types, 213-217
regulatory challenges for, 217
safety assessments of, 217
screening and, 215
in vitro vs *in vivo* assays, 216-217
Vantin, 120t. *See also* Cefpodoxime/cefprozime proxetil.
Velosef, 120t. *See also* Cephadrine.

Wald scores, 29-31, 34t. *See also* Clinical diagnoses.
WBC (white blood cell) counts, elevated, 29-30, 31t

XL (extended-release) clarithromycin filmtabs, 98. *See also* Clarithromycin.
Z Pak azithromycin, 110. *See also* Azalides and azithromycin.